Navigation Links
Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
Date:11/1/2007

Data Presented at the 2nd Annual International Workshop on Hepatitis C

Resistance & New Compounds

WATERTOWN, Mass., Nov. 1 /PRNewswire/ -- Researchers from Enanta Pharmaceuticals today presented data on novel Hepatitis C protease inhibitors with potent antiviral activity in the cell-based replicon assay and favorable pre-clinical pharmacokinetic properties with the potential for once-daily dosing in humans.

The hepatitis C virus (HCV) increases a person's chances of developing chronic liver disease, and affects more than 170 million people worldwide. Current treatment options are not sufficient. Specifically targeted antiviral therapies for HCV, such as NS3/4a protease inhibitors, may have the potential to increase the proportion of patients in whom the virus can be eradicated.

The abstract, "Potent HCV protease inhibitors with the potential for once-daily dosing," was presented today in a session focused on protease inhibitors at 8:30 a.m. during the 2nd Annual International Workshop on Hepatitis C Resistance & New Compounds in Boston.

"These compounds have demonstrated remarkable potency in the antiviral replicon assay and favorable pre-clinical pharmacokinetic properties supporting the potential for once-daily dosing in humans," said Yat Sun Or, Senior Vice President, Research and Development of Enanta Pharmaceuticals. "These data demonstrate our commitment to the discovery of next-generation protease inhibitors that will enhance the treatment options for patients who are infected with hepatitis C."

Abbott and Enanta Pharmaceuticals formed a collaboration in 2006 to develop and commercialize HCV protease inhibitors. The partnership leverages Abbott's innovative work in the protease inhibitor field against the Human Immunodeficiency Virus (HIV) and leadership in the area of antiviral therapies and Enanta's core expertise in chemistry and drug discovery. The HCV NS 3/4A serine protease is the focus of the collaboration.

About Hepatitis C Virus

Hepatitis C is a liver disease affecting over 170 million people worldwide. The virus is spread through direct contact with the blood of an infected person. Hepatitis C increases a person's risk of developing chronic liver disease, cirrhosis, liver cancer and death. Liver disease associated with HCV infection is growing rapidly, and current therapies only provide sustained benefit in about half of patients with the genotype1 form of the virus.

About Enanta

Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best in class small molecule drugs in the anti-infective field. At the heart of Enanta is its commitment to innovative chemistry that surpasses traditional medicinal chemistry approaches. Enanta is developing novel protease and polymerase inhibitors targeted against the Hepatitis C virus (HCV). Additionally, the Company has created a new class of macrolide antibiotics, called Bicyclolides that overcomes bacterial resistance. Antibacterial focus areas include superbugs, respiratory tract infections, and intravenous and oral treatments for hospital and community MRSA. Enanta is a privately held company with offices in Watertown, MA. More information about the company can be found at http://www.enanta.com.

Enanta Contact

For Enanta Investor Relations, please contact:

Paul Mellett

617-607-0761

For Enanta Public Relations, please contact:

Jennifer Greenleaf

MacDougall Biomedical Communications

508-647-0209


'/>"/>
SOURCE Enanta Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. New Information on the Potential of Plasmin Shared at ISTH Congress
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
5. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
6. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
7. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
8. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
9. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
10. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
11. New Study Shows That telmisartan has Greater Renoprotective Potential Thanlosartan in Hypertensive Patients With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- , , , WHEN: , ... , , , LOCATION: , , , Online, with free ... EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice President ... Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... is witnessing an exceptional era. Several new demand spaces, such as ...
(Date:6/23/2016)... , June 23, 2016 Revolutionary ... Oticon , industry leaders in advanced audiology ... of Oticon Opn ™, the world,s first internet ... possibilities for IoT devices.      (Photo: ... introduces a number of ,world firsts,: , ...
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):